Thyronamine
|
WikiDoc Resources for Thyronamine |
|
Articles |
|---|
|
Most recent articles on Thyronamine Most cited articles on Thyronamine |
|
Media |
|
Powerpoint slides on Thyronamine |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Thyronamine at Clinical Trials.gov Clinical Trials on Thyronamine at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Thyronamine
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Thyronamine Discussion groups on Thyronamine Patient Handouts on Thyronamine Directions to Hospitals Treating Thyronamine Risk calculators and risk factors for Thyronamine
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Thyronamine |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Thyronamine refers both to a molecule, and to derivatives of that molecule: a family of decarboxylated and deiodinated metabolites of the thyroid hormones thyroxine (T4) and 3,5,3'-triiodothyronine (T3).
The group includes:
- Thyronamine (T0AM)
- 3-Iodothyronamine (T1AM), which is the most notable one as it is a trace amine found in the nervous system. It is a possible candidate for the natural ligand of the trace amine-associated receptor TAAR1 (TAR1), a G protein-coupled receptor located in the cell membrane.
- 3,5-Diiodothyronamine (T2AM)
- 3,5,3'-Triiodothyronamine (T3AM)
See also